Skip to content
Lentiviral Transient and Stable Platforms

Lentiviral Transient and Stable Platforms

Engineered viral vectors are effective tools for the development of cell and gene therapies targeting a range of diseases. Current vector manufacturing approaches primarily use fully transient, adherent processes, bringing associated issues of robustness, scalability and high cost-of-goods. To address these issues, we set out to improve the lentiviral (LV) plasmid systems and develop enhanced cGMP compliant, suspension, HEK293 cell lines for both transient and stable manufacture.

Via the genetic optimisation of the lentiviral packaging plasmids, we demonstrate 20-100% increase in infectious titres compared to competitor products. We’ve also selected a clonal suspension HEK293 cell line for improved viral vector productivity, and it consistently achieves infectious titre of above 1E8 TU/mL in our preferred manufacture process, optimised in both shake flask and bioreactor formats.

Download the resource to read on...

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of qualify control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.